 "Suven Life receives patent for CNS drug in Mexico and Singapore")
Suven Life Sciences Ltd has been granted product patent from Mexico and Singapore for new chemical entities (NCEs) used for the treatment of disorders associated with neurodegenerative or central nervous system (CNS) diseases. These patents are valid through 2029.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of 18 granted patents from Mexico and 20 granted patents from Singapore. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for major depressive disorder (MDD) with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of 18 granted patents from Mexico and 20 granted patents from Singapore. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for major depressive disorder (MDD) with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.